Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII - clarification of Kogenate inhibitor data - Response

被引：0
|
作者：
Gringeri, A [1 ]
机构：
[1] Mangiagalli & Regina Elena Hosp Fdn, IRCCS Maggiore, A Bianchi Bonomi Haemophilia & Thrombosis Ctr, Milan, Italy
[2] Univ Milan, Milan, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2005年 / 130卷 / 01期
关键词：
B-domain-deleted FVIII; haemophilia A; inhibitors; recombinant FVIII;
D O I：
10.1111/j.1365-2141.2005.05552.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：146 / 147
页数：3
相关论文
共 50 条
  • [41] PROPHYLACTIC TREATMENT WITH A B-DOMAIN-DELETED RECOMBINANT FACTOR-VIII (R-VII SQ) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA-A
    BERNTORP, E
    BRACKMANN, HH
    DECHAVANNE, M
    GAZENGEL, C
    JOHNSSON, H
    LAURIAN, Y
    TENGBORN, L
    STAHL, C
    HOLM, R
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1011 - 1011
  • [42] Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B
    Yang, R.
    Zhao, Y.
    Wang, X.
    Sun, J.
    Jin, J.
    Wu, D.
    Charnigo, R.
    O'Brien, A.
    Zhong, Z.
    Rendo, P.
    HAEMOPHILIA, 2012, 18 (05) : E374 - E378
  • [43] DETERMINING INHIBITOR-DEVELOPMENT RISK IN PREVIOUSLY UNTREATED HEMOPHILIA-A PATIENTS TREATED (PUPS) WITH RECOMBINANT FACTOR-VIII (RECOMBINATE(TM))
    LEE, ML
    COURTER, S
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 856 - 856
  • [44] INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA RECEIVING KOGENATE - 4.5 YEAR FOLLOW-UP DATA, INCLUDING RESPONSE TO IMMUNE TOLERANCE (IT) WITH KOGENATE
    LUSHER, J
    ARKIN, S
    ABILDGAARD, C
    INWOOD, M
    HILGARTNER, M
    HURST, D
    PEDIATRIC RESEARCH, 1994, 35 (04) : A165 - A165
  • [45] INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATMENT PATIENTS (PUPS) WITH HEMOPHILIA RECEIVING KOGENATE - 4.5 YEAR FOLLOW-UP DATA, INCLUDING RESPONSE TO IMMUNE TOLERANCE (IT) WITH KOGENATE
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    INWOOD, M
    ZIMMERMANN, R
    HILGARTNER, M
    HURST, D
    BLOOD, 1993, 82 (10) : A153 - A153
  • [46] Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy
    Ellsworth, Patrick
    Chen, Sheh-Li
    Key, Nigel
    Abajas, Yasmina
    Ma, Alice
    HAEMOPHILIA, 2021, 27 (01) : E147 - E150
  • [47] Inhibitor Development and Efficacy in Previously Untreated Patients with Severe Haemophilia A Treated with Human-cl rhFVIII*, a New Generation Recombinant FVIII of Human Origin
    Liesner, R.
    Jansen, M.
    Belyanskaya, L.
    Neufeld, E.
    HAEMOPHILIA, 2017, 23 : 25 - 26
  • [48] Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review
    Hassan, S. .
    Cannavo, A.
    Gouw, S. C.
    Rosendaal, F. R.
    van der Bom, J. G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (06) : 1055 - 1068
  • [49] Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors
    Mahlangu, J. N.
    Andreeva, T. A.
    Macfarlane, D. E.
    Walsh, C.
    Key, N. S.
    HAEMOPHILIA, 2017, 23 (01) : 33 - 41
  • [50] Monitoring of factor VIII level in patients treated with B-domain deleted recombinant FVIII (ReFacto®).: A need for standardization.
    Toulon, PA
    Santos, MD
    BLOOD, 2002, 100 (11) : 698A - 698A
12345